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ABSTRACT
Objectives: To determine the effectiveness of a single
perioperative prophylactic 2 g dose of cephalexin in
preventing surgical site infection (SSI) following
excision of skin lesions from the lower limb.
Design: Prospective double-blinded placebo-
controlled trial testing for difference in infection rates.
Setting: Primary care in regional North Queensland,
Australia.
Participants: 52 patients undergoing lower limb skin
lesion excision.
Interventions: 2 g dose of cephalexin 30–60 min
before excision.
Main outcome measures: Incidence of SSI.
Results: Incidence of SSI was 12.5% (95% CI 2.7%
to 32.4%) in the cephalexin group compared with
35.7% (95% CI 18.6% to 55.9%) in the placebo group
(p=0.064). This represented an absolute reduction of
23.21% (95% CI −0.39% to 46.82%), relative
reduction of 65.00% (95% CI −12.70% to 89.13%)
and number-needed-to-treat of 4.3.
Conclusions: Administration of a single 2 g dose of
cephalexin 30–60 min before skin lesion excision from
the lower limb may produce a reduction in the
incidence of infection; however, this study was
underpowered to statistically determine this.
Trial registration number: ACTRN12611000595910.
INTRODUCTION
Skin cancer causes a significant burden of
disease in many developed countries.1 2 The
majority of skin cancers are treated by surgi-
cal excision3 4 which is increasingly being
performed in outpatient and primary care
settings.5 6 As the majority of skin cancer
surgery takes place in general practice in
Australia,5 it is important to study infection
rates in this setting. Skin lesion excisions
form a large proportion of a typical
Australian general practitioner’s (GPs)
workload, and this proportion is even greater
for Queensland GPs, given that this State has
the highest incidence of skin cancer.6
General practice dermatological surgery may
differ from a hospital setting, with most pro-
cedures taking place in treatment rooms
rather than in formal operating theatres.
Surgical site infection (SSI) is one of the
few complications of this relatively minor
surgery. These infections often require anti-
biotics and repeat consultations to assess
wound healing. They can potentially lead to
significant bacteraemic complications and
impair cosmetic outcome.7 The acceptable
rate of infection following clean minor
surgery (class 1) is less than 5%.8–12 This is
reflected in skin lesion excisions, with a rate
of between 1% and 3% in most studies.13–18
The exceptions are studies conducted by the
present authors in 2005 and 2009 which
reported infection rates of 8.6% and
11.7%.19 20 The reason for this higher infec-
tion rate remains unclear, but might be
related to tropical humidity. Even within
cohorts with a low overall incidence of infec-
tion, some procedures may be at higher risk
because of the body site, pathology or
patient factors and infection rates may be
greater than 5% in these high-risk groups.
Previously identified risk factors include
Strengths and limitations of this study
▪ Blinded randomised design with placebo control.
▪ Standardised protocol for excision and follow-up.
▪ Collection of a large amount of demographic,
medical and excision-related data for comparison
of groups.
▪ Underpowered study due to small sample size.
▪ Higher than anticipated infection rate with no
clear underlying reason.
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excisions from the region of the lower leg, ear and
nose,16 20–22 excisions of skin cancers20 21 and excisions
from patients with diabetes.20 In tropical North
Queensland, the infection rates following excisions from
the lower limb ranged from 14.75% to 18.18%.19 20
Several expert groups—including the Mayo Clinic’s
Department of Dermatological Surgery7 23 24—have sug-
gested that a single oral dose of perioperative antibiotic
prophylaxis may be indicated in certain ‘high risk’ situa-
tions such as excisions from the lower limb. If effective,
this may be a low-cost and easily implemented method
of reducing the incidence of SSI in selected situations.
Recommendations such as these are however yet to be
tested in clinical trials.
This trial sought to determine the efficacy of a 2 g
dose of cephalexin given 30–60 min prior to skin lesion
excision from the lower limb in preventing the subse-
quent development of an SSI.
METHODOLOGY
Trial design
We carried out a randomised double-blind placebo-
controlled trial involving patients presenting for minor
skin excisions from the lower limb.
Setting and participants
The study was conducted in two private general practices
in Mackay, Queensland (latitude 21E8S; inhabitants
77 29325) between September 2011 and May 2012. One of
the participating practices was an open access designated
skin cancer clinic which was run by two GPs specialising in
skin cancer management. The other centre offered a full
range of primary care services and all doctors working at
the practice were involved in the study.
Consecutive patients presenting at either practice for a
skin lesion excision from the lower limb were invited to
participate. Exclusion criteria are shown in box 1. For
patients having multiple excisions meeting inclusion cri-
teria on the same or subsequent days, data were only
analysed for the first excision conducted which met the
inclusion criteria.
Demographic information was collected as well as clin-
ical information about diabetes, anticoagulation and any
other predetermined significant medical conditions. A
body site map was used to record the excision site. At
the end of the study, practice nurses were asked to
re-examine computer records to fill in any missing data.
The principal researcher visited participating GPs and
practice nurses prior to the start of and regularly during
the trial to ensure that data collection was standardised.
Intervention and control
The intervention arm of the trial consisted of a 2 g dose
of cephalexin administered 30–60 min before an exci-
sion. The cephalexin (Keflex 500 mg capsules)was com-
pounded into generic gel capsules (SurgiPack Empty
Gelatine Capsules, Size ‘00’, 0.95 mL capacity). Rice
flour was used to fill the placebo capsules as it had an
identical appearance to the cephalexin powder and no
foreseeable adverse effects. Each dose consisted of four
capsules filled with either cephalexin or rice flour.
Randomisation and blinding
A computer-generated random number table was used
to randomise a consecutive sequence of numbers into
two groups—intervention and control—in permuted
blocks of 20 with a 1:1 ratio. These numbers were used
to label medicine jars containing the corresponding cap-
sules. The content of the individual jar was known only
to the principal researcher who had no direct involve-
ment with participants or in data collection. All others
involved in the trial were blinded to the capsule identity.
Participant recruitment and trial protocol
Eligible participants were identified by a practice nurse
or doctor at the time of their pre-excision appointment.
All patients provided signed consent before enrolling in
the study. Participants were given a numbered medicine
jar along with written and verbal instructions to take the
four capsules 30–60 min before their excision
appointment.
Surgical wound management protocol
Workshops were run at the participating practices to
develop guidelines to ensure that excision management
was standardised. The excision was performed using an
aseptic technique and skin preparation with 2% chlorhexi-
dine solution. Wounds were dressed with non-waterproof
adhesive fabric dressings. Patients were provided with
verbal and written instructions regarding wound care,
including the need for wounds to be kept dry and covered
for the first 2 days and for topical antiseptics or antibiotics
not to be used. Time to removal of sutures (ROS) was 12–
16 days at the treating doctor’s discretion.
Outcome measures
Wounds were assessed for infection by the practice nurse
or doctor at the time of ROS, or sooner if patients
re-presented earlier with a perceived infection. Our def-
inition of SSI was based on the presence of any of the
criteria shown in box 2. These were adapted from the
Box 1 Exclusion criteria for participant recruitment
<18 years old or not capable of providing informed consent.
Declined to participate.
Currently taking antibiotics or treating clinician feels they are clin-
ically indicated for antibiotic treatment following excision.
Repair of lacerations or lesions considered as contaminated/
infected prior to surgery.
Excision not utilising primary closure (eg, shave biopsy or
curette).
Excision of a sebaceous cyst.
Patient unable to return for suture removal.
Penicillin or cephalosporin allergy.
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Centre for Disease Control and Prevention (CDC) defin-
ition for superficial SSI.26 Information was also collected
on wound swabs performed, prescription of antibiotics
and number of follow-up visits. Patients were asked
about any adverse effects which could be attributed to
the trial medication.
Sample size
Our sample size was calculated on the basis of previous
studies19 20 which predicted a baseline infection rate of
15% from the lower limb. We decided that an absolute
reduction in the SSI rate of 10% or more would be clin-
ically significant. To reach this conclusion with statistical
confidence (power 80%, α error 5%), it was calculated
that a sample size of 282 excisions would be required.
The trial was conducted as part of an honours
research project which ran over a 2-year period. The
decision was made to cease data collection once the
desired sample size of 282 was collected or by May 2012
to allow time for completion of the honours thesis.
Statistical methods
Data were entered and stored in a Microsoft Access data-
base and statistical analysis and tests conducted in IBM
SPSS Statistics V.20. Numeric data were summarised
using median values and IQRs. Categorical variables
were reported as proportions with Clopper-Pearson 95%
CIs calculated for incidence of infection.
Fisher’s exact test was used to test the primary hypoth-
esis; absolute and relative risk reductions were calculated
with 95% CIs as well as the number-needed-to-treat
(NNT). Comparison of other infection-related para-
meters, such as prescription of antibiotics and number
of additional visits, was conducted with Fisher’s exact
test and Mann-Whitney U tests, respectively.
No provisions were made for an interim analysis as it
was felt that there was low risk of potential harm.
Ethics approval and trial registration
The trial was registered on the Australian New Zealand
Clinical Trials Registry (ACTRN: 12611000595910) prior
to its start.
RESULTS
Of a total of 78 excisions from the lower limb conducted
during the collection period, 26 cases were excluded
from the study (figure 1). Fifty-two cases were subse-
quently randomised and underwent skin lesion excision.
Three participants forgot to take the trial medication
prior to their excision, and one participant treated his
wound with a topical antiseptic. Follow-up was com-
pleted in all 52 (100%) participants randomised. Six
doctors across the two practices were involved, each
recruiting between 3 and 18 patients.
Baseline characteristics
Comorbid conditions (excluding diabetes) were more
common among those cases randomised to the cepha-
lexin group compared with placebo (87.5% vs 67.9%)
and antihypertensive use was also higher (70.8% vs
Box 2 Criteria for presence of a surgical site infection*
Purulent discharge.
Erythema >1 cm from the wound margin.
Localised swelling.
Patient reports increased tenderness at the wound site.
Patient reports increased heat at the wound site.
*Presence of any one or more of these criteria was deemed to
represent the presence of a surgical site infection.
Figure 1 Trial profile (ROS,
removal of sutures).
Smith SC, et al. BMJ Open 2014;4:e005270. doi:10.1136/bmjopen-2014-005270 3
Open Access
 group.bmj.com on September 23, 2014 - Published by bmjopen.bmj.comDownloaded from 
50%). The median excision size was 6 mm smaller in
the cephalexin group (table 1).
Outcome measures and estimates
The primary intention-to-treat analysis was conducted on
all 52 cases which were randomised and in which the
excision was performed (table 2). A secondary per
protocol analysis was also performed that examined only
cases where patients took their allocated trial medication
and did not violate trial protocol (table 3).
In the intention-to-treat analysis, the incidence of SSI
in the intervention group was 12.5% (3/24) compared
with 35.7% (10/28) in the control group. This
approached statistical significance (p=0.064), producing
an absolute reduction of 23.21% (95% CI −0.39% to
46.82%), relative reduction of 65.00% (95% CI −12.70%
to 89.13%) and an NNT of 4.3.
There were also clinically relevant reductions in anti-
biotic prescriptions and follow-up visits. These were also
not of statistical significance (table 2).
In the per protocol analysis, the difference in incidence
of infection was statistically significant (8.7% (2/23) vs
36% (9/25); p=0.039). The relative risk reduction for an
SSI produced by prophylaxis was 75.85% (95% CI −0.30%
to 94.18%), resulting in an absolute risk reduction of
27.30% (95% CI −3.50% to 51.10%) and an NNTof 3.7.
No adverse effects attributed to the trial medication
were reported by participants.
DISCUSSION
In this trial, a 2 g dose of cephalexin 30–60 min before
skin lesion excision from the lower limb was associated
with a relative reduction in infection rate of 65% and an
absolute reduction of 23.2% from a baseline infection
rate of 35.7–12.5%. Based on these findings, the NNT
with prophylactic cephalexin was 4.31 in order to
prevent one infection following excision from the lower
limb. Additionally, prophylaxis resulted in a reduction in
the number of therapeutic antibiotic courses required
and number of follow-up visits.
Table 1 Baseline characteristics*
Cephalexin (n=24) Placebo (n=28)
Age (years) 69.5 [61.25–78.75] 69.5 [59.25–75.75]
Male 54.2 (13) 53.6 (15)
Occupation
Retired 58.3 (14) 60.7 (17)
Unemployed 0 (0) 10.7 (3)
Working 41.7 (10) 28.6 (8)
Smoking status
Current smoker 8.3 (2) 7.1 (2)
Ex-smoker 50 (12) 35.7 (10)
Never smoked 41.7 (10) 57.1 (16)
Alcohol consumption
Non-drinker 45.8 (11) 32.1 (9)
Occasional (<1 day/week) 16.7 (4) 21.4 (6)
Weekly 37.5 (9) 39.3 (11)
Comorbid conditions† 87.5 (21) 67.9 (19)
Diabetes 25.0 (6) 21.4 (6)
Anticoagulant use‡ 29.2 (7) 25 (7)
Antihypertensive use 70.8 (17) 50.0 (14)
Time from pill consumption to excision (min) 61.5 [50–75] 60 [48.25–65.75]
Below knee 83.3 (20) 82.1 (23)
Excision size (mm) 22.5 [17.25–31.75] 28.5 [22–36]
Type of repair
Simple closure 45.8 (11) 60.7 (17)
Two-layer closure 50 (12) 32.1 (9)
Skin flaps 4.2 (1) 7.1 (2)
Histology
NMSC 75.0 (18) 75.0 (21)
Melanoma 4.2 (1) 3.6 (1)
Other benign 21.4 (6) 29.2 (7)
*Data are median [IQR] or percentage (number).
†Comorbid conditions included; cephalexin group: hypertension (n=15), COPD 3, regular oral steroids (n=0), regular inhaled steroids (n=0),
PVD (n=1), IHD (n=0) current cancer (n=0), other (n=12); placebo group: hypertension (n=11), COPD 1, regular oral steroids (n=0), regular
inhaled steroids (n=1), PVD (n=0), IHD (n=1) current cancer (n=0), other (n=14).
‡Cephalexin group: aspirin (n=7), clopidogrel (n=0) and/or warfarin (n=1); placebo group: aspirin (n=5), clopidogrel (n=1) and/or warfarin
(n=1).
COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; NMSC, non-melanomatous skin cancers; PVD, peripheral
vascular disease.
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Limitations
Although these findings met our predetermined level
for clinical relevance, an absolute reduction of infection
rate by 10%, they were not statistically significant
(p=0.064). Furthermore, a slower than predicted recruit-
ment rate, and time constraints of the honours research
project, resulted in the trial being terminated well
before the calculated sample size was achieved. As such,
this trial was unable to address the proposed hypothesis
and no definitive conclusions can be drawn from it on
the actual efficacy of antibiotic prophylaxis.
Various characteristics influence SSI and although
information on as many variables as possible was
recorded, it is difficult to ensure that all baseline data
are comparable. Several characteristics did vary notably
between the prophylaxis and placebo groups in this
study. Given that the study was underpowered and did
not achieve statistical significance, it was decided not to
pursue adjustment for these imbalances using multiple
logistic regression. Future studies, appropriately powered
to address this hypothesis, will need to adjust for such
baseline difference as well as consider cluster analysis
based on individual GPs to limit the confounding effect
on variable training, experience and outcomes among
practitioners.
Even when using guidelines, the diagnosis of infection
is still subjective and there may be interobserver and
intraobserver variation.27 The 1992 CDC definition of
SSI that we chose to use has limitations. However, it is
the most widely implemented standard definition of
wound infection27 and is the closest to a gold standard
available. We have no evidence to support intrapractice
and interpractice reproducibility of measurement and
recording procedures. This is also an area which future
studies may consider addressing.
Generalisability
The baseline infection rate for lower limb excisions in
this trial was considerably higher than that reported
in other studies, including those previously conducted
in Mackay.19 20 The underlying reason for this is uncer-
tain, but may be related to the majority of the excisions
being from below the knee, a site that has previously
been identified as being at an even higher risk of infec-
tion. Furthermore, the infection rate in studies con-
ducted in Mackay has consistently been higher than that
reported in other centres. This further adds to the argu-
ment that climate/environmental factors may be import-
ant determinants of SSI following skin lesion excision.
Owing to the higher than expected infection rate, there
Table 2 Primary and secondary outcome measures intention-to-treat analysis*
Cephalexin (n=24) Placebo (n=28) Risk difference (95% CI) p Value
Number of infections 3 10 0.35 (0.11 to 1.13) 0.064
Infection rate (95% CI) 12.5 (2.7 to 32.4) 35.7 (18.6 to 55.9) NA
Prescription of antibiotics 3 6 0.58 (0.16 to 2.09) 0.480
Number of additional follow-up visits required
Median 0 [0–0] 0 [0–1] NA 0.164
Total (Range) 7 (0–3) 26 (0–10) NA
Additional total amount of antibiotics (excluding prophylaxis) (mg)†
Median 0 [0–0] 0 [0–0] NA 0.290
Total (Range) 27 000 (0–12 000) 146 750 (0–66 750) NA
*Data are median (IQR) (range) or number (%) unless otherwise stated; 95% CI for infection rate are the Clopper-Pearson interval; p values
are Fisher’s exact test or the Mann-Whitney U test for categorical and continuous variables, respectively.
†Cephalexin group: cephalexin (15 000 mg), flucloxacillin (12 000 mg); placebo group: cephalexin (100 000 mg), flucloxacillin (24 000 mg);
ciprofloxacin (14 000 mg), amoxicillin/clavulonic acid (8750 mg).
NA, not applicable.
Table 3 Primary and secondary outcome measures per protocol analysis*
Cephalexin (n=23) Placebo (n=25) Risk difference (95% CI) p Value
Number of infections 2 9 0.24 (0.06 to 1.00) 0.039
Infection rate (95% CI) 8.7 (1.1 to 28.0) 36.0 (18 to 57.5) NA
Prescription of antibiotics 2 (8.7%) 6(24.0%) 0.36 (0.08 to 1.62) 0.249
Number of additional follow-up visits required
Median 0 [0–0] 0 [0–1] NA 0.058
Total 5 26 NA
95% CI for infection rates are the Clopper-Pearson interval.
*Data are median [IQR] or number (%) unless otherwise stated; 95% CI for infection rate are the Clopper-Pearson interval; p values are
Fisher’s exact test or the Mann-Whitney U test for categorical and continuous variables, respectively.
NA, not available.
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may be limitations to extrapolating these results to other
centres, where the baseline infection is lower. However,
similar relative reductions have been produced with
prophylactic regimens, including single dose parenteral
antibiotics, in settings with lower baseline infection rates
(table 4).
Antibiotic prophylaxis is probably prescribed exces-
sively or inappropriately for dermatological surgery and
is thought to be best reserved for high-risk patients such
as excisions from the lower limb.7 23 24 There are no
data available on the current prescribing habits of
Australian GPs regarding oral prophylaxis for minor
excisions. The decision to prescribe antibiotic prophy-
laxis is complicated; in addition to efficacy, antibiotic
costs, adverse effects and resistance must also be taken
into account.
The role of antibiotic prophylaxis in the prevention of
SSI following skin lesion excision remains controver-
sial.32 Randomised trials have demonstrated that topical
antibiotic prophylaxis is ineffective and should not be
used.33 34 Infusion of antibiotic mixed with local
anaesthetic, and systemic prophylactic regimes, have pro-
duced significant reductions in infection rates.31 29 35 36
The limited available literature has demonstrated
comparable relative reductions in SSI to this study
(table 4).28–31 Two of these studies examined the use of
oral prophylaxis28 30 while the other two considerably
larger studies examined various regimens of intramuscu-
lar cefazolin.31 29 With the exception of Amland et al28
and one arm of the 1994 study by Bencini et al,29 all of
these studies examined short courses of prophylaxis
rather than single doses. Although variations in the
study populations and protocols make comparison diffi-
cult, the reductions achieved in this study appear to be
at least similar to those achieved with short courses of
prophylaxis and parenteral methods of delivery.
CONCLUSION
In this study, a 2 g dose of cephalexin 30–60 min before
skin lesion excisions from the lower limb was associated
with a reduced risk of SSI from 35.7% to 12.5%,
Table 4 Studies of systemic antibiotic prophylaxis for skin lesion excision
Study,
country
Setting and
sample size Intervention and control Wound type
Infection rate
(relative reduction)
Amland
et al,28
Norway
Plastic surgery
unit, 60 patients
Control: placebo
Intervention: single dose 1000 mg
orally azithromycin the night before
surgery
Skin cancer surgery Control: 16.0%
Azithromycin: 5.7%
(0.36)
Bencini
et al,29 Italy
Outpatient
dermatologic
surgery unit,
527 patients
A: no prophylaxis
B: 1 g intramuscular cefazolin 12
hourly for 48 h before and after
surgery
C: 1 g intramuscular cefazolin 12
hourly from 2 h before surgery to 24 h
after
D: single 1 g intramuscular dose
cefazolin 2 h before surgery
Excisions from
contamination- prone areas
(groin, axillae, interdigital
spaces of feet)
A: 12%
B: 4.6% (0.38)*
C: 0.77% (0.064)*
D: 2% (0.17)*
Czarnecki
et al,30
Australia
Outpatient
dermatology
clinic,
97 lesions
Intervention 1: 500 mg orally
cephalexin three times a day, starting
2 days before and continuing 24 h
postoperatively
Intervention 2: topical mupirocin three
times a day from 2 days before and
continuing 24 h postoperatively
Control: cetrimide-chlorhexidine cream
2 days before and continuing 24 h
postoperatively
Ulcerated skin cancers which
cultured positive for
Staphylococcus aureus or
Gram-negative bacteria
Control: 21.7%
Intervention
1: 2.7% (0.12)*
Intervention
2: 0% (0)*
Bencini
et al,31 Italy
Outpatient
dermatologic
surgery unit,
2165 patients
A: no antibiotic
B: 1 g intramuscular cefazolin 12
hourly immediately after surgery
continuing for 3 days
C: 250 mg cefazolin powder applied
locally during surgery
D: 1 g cefazolin intramuscular 12
hourly starting 2 days before and
continuing 2 days after surgery
Excision of skin lesions A: 4.3%
B: 1.5% (0.35)*
C: 0.9% (0.21)*
D: 0.2% (0.047)*
*Statistically significant reduction compared to control.
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producing an absolute reduction of 23.2%, a relative
reduction of 65% and an NNT of 4.3. This reduction,
however, was not statistically significant (p=0.064), and
the trial was underpowered to address the hypothesis. As
such, no definitive conclusion can be drawn on the effi-
cacy of oral prophylaxis for lower limb skin lesion exci-
sion from this trial. Given the potential benefits, further
investigation is warranted.
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